MedTrace Logo

Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

NCT00185731 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-12-02

Study results available
· View outcomes & findings →

Summary

This is an approach which can inflict significant toxicity. An alternative is to block expression of oncogenes which are over-expressed only in cancer cells, a therapeutic approach which could reduce toxicity to the host while maximizing destruction of the oncogene-dependent malignant cells.

Conditions

Interventions

DRUG

Atorvastatin

80 mg orally once daily

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Damon Runyon Cancer Research Foundation

    collaborator OTHER

  • Burroughs Wellcome

    collaborator INDUSTRY

  • Dean Felsher

    lead OTHER

Principal Investigators

  • Dean Felsher · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2012-11-30
Completion
2012-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185731 on ClinicalTrials.gov